Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMRA NASDAQ:NXTC NASDAQ:PLUR NASDAQ:QNTM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$1.59$1.94$1.57▼$4.60$4.90M0.335,995 shs17,387 shsNXTCNextCure$4.24$3.91$1.55▼$15.74$15.31M1.426.24 million shs281,180 shsPLURPluri$1.78$2.15$1.56▼$5.68$19.21M0.6447,124 shs9,360 shsQNTMQuantum Biopharma$2.99$4.48$2.07▼$31.91$19.14M0.4393,095 shs37,263 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica0.00%-3.47%-9.43%-27.29%-59.46%NXTCNextCure0.00%-29.22%+157.75%-55.93%-31.28%PLURPluri0.00%-4.30%-19.64%-47.85%-65.50%QNTMQuantum Biopharma0.00%-7.72%-21.32%-32.81%-88.11%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMRABiomerica$1.59$1.94$1.57▼$4.60$4.90M0.335,995 shs17,387 shsNXTCNextCure$4.24$3.91$1.55▼$15.74$15.31M1.426.24 million shs281,180 shsPLURPluri$1.78$2.15$1.56▼$5.68$19.21M0.6447,124 shs9,360 shsQNTMQuantum Biopharma$2.99$4.48$2.07▼$31.91$19.14M0.4393,095 shs37,263 shs The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMRABiomerica0.00%-3.47%-9.43%-27.29%-59.46%NXTCNextCure0.00%-29.22%+157.75%-55.93%-31.28%PLURPluri0.00%-4.30%-19.64%-47.85%-65.50%QNTMQuantum Biopharma0.00%-7.72%-21.32%-32.81%-88.11%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMRABiomerica 1.00Sell$9.00467.82% UpsideNXTCNextCure 2.25Hold$19.00348.11% UpsidePLURPluri 1.00SellN/AN/AQNTMQuantum Biopharma 1.00SellN/AN/ACurrent Analyst Ratings BreakdownLatest BMRA, PLUR, NXTC, and QNTM Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/23/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/15/2026NXTCNextCure HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.007/7/2026NXTCNextCure Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/7/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)6/16/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/11/2026NXTCNextCure Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong Sell ➝ Hold6/5/2026BMRABiomerica Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/2/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/28/2026QNTMQuantum Biopharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/21/2026BMRABiomerica Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026PLURPluri Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)(Data available from 7/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMRABiomerica$4.33M1.13N/AN/A$1.61 per share0.98NXTCNextCureN/AN/AN/AN/A$9.97 per shareN/APLURPluri$1.34M14.33N/AN/A($0.11) per share-16.18QNTMQuantum BiopharmaN/AN/AN/AN/A$1.34 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMRABiomerica-$4.97M-$0.89N/AN/AN/A-96.49%-98.14%-70.42%8/27/2026 (Estimated)NXTCNextCure-$55.84M-$17.19N/AN/AN/AN/A-186.96%-124.62%8/6/2026 (Estimated)PLURPluri-$22.58M-$4.53N/AN/AN/A-2,162.08%N/A-106.59%9/23/2026 (Estimated)QNTMQuantum Biopharma-$26.17M-$8.25N/AN/AN/AN/A-941.54%-224.41%8/6/2026 (Estimated)Latest BMRA, PLUR, NXTC, and QNTM EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/6/2026Q2 2026NXTCNextCure-$1.98N/AN/AN/AN/AN/A8/6/2026N/AQNTMQuantum Biopharma-$0.4116N/AN/AN/AN/AN/A5/14/2026Q3 2026PLURPluri-$0.66-$0.55+$0.11-$0.55$0.66 million$0.17 million5/7/2026Q1 2026NXTCNextCure-$2.1050-$1.87+$0.2350-$1.87N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMRABiomericaN/AN/AN/AN/AN/ANXTCNextCureN/AN/AN/AN/AN/APLURPluriN/AN/AN/AN/AN/AQNTMQuantum BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMRABiomericaN/A2.641.59NXTCNextCureN/A4.614.61PLURPluriN/A0.330.33QNTMQuantum BiopharmaN/A0.630.63Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMRABiomerica22.28%NXTCNextCure42.65%PLURPluri16.59%QNTMQuantum Biopharma1.24%Insider OwnershipCompanyInsider OwnershipBMRABiomerica18.00%NXTCNextCure11.90%PLURPluri43.16%QNTMQuantum Biopharma8.53%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMRABiomerica603.09 million2.53 millionNo DataNXTCNextCure903.61 million3.18 millionNo DataPLURPluri15010.79 million6.13 millionNo DataQNTMQuantum BiopharmaN/A6.40 million5.85 millionN/ABMRA, PLUR, NXTC, and QNTM HeadlinesRecent News About These CompaniesQuantum BioPharma (QNTM) Developing Two-Pronged Attack on Brain Disorders Affecting MillionsJuly 22, 2026 | finance.yahoo.comQuantum BioPharma Announces Intention to Settle DebtJuly 20, 2026 | globenewswire.comQuantum Biopharma (NASDAQ:QNTM) Lowered to Strong Sell Rating by Wall Street ZenJuly 18, 2026 | americanbankingnews.comQuantum BioPharma (QNTM) Expands Clinical Development of Neuroprotective TherapyJuly 15, 2026 | finance.yahoo.comWhy Quantum BioPharma (QNTM) Is 'One to Watch'July 10, 2026 | finance.yahoo.comQuantum BioPharma Provides Corporate UpdateJuly 7, 2026 | globenewswire.comQuantum BioPharma (QNTM) Showcases Unique MS Drug Candidate, Growth Strategy During Executive PodcastJuly 2, 2026 | finance.yahoo.comQuantum BioPharma (QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging StudyJune 29, 2026 | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Reaches Key Midpoint Milestone in Multiple Sclerosis Imaging StudyJune 29, 2026 | markets.businessinsider.comNetworkNewsAudio Announces Audio Press Release (APR) the Advancement of First-in-Class Treatment for Multiple SclerosisJune 26, 2026 | globenewswire.comThe Quest to Repair What Multiple Sclerosis Takes AwayJune 25, 2026 | markets.businessinsider.comQuantum BioPharma Ltd. (NASDAQ: QNTM) Advancing Innovative, First-in-Class, Patented MS TherapyJune 25, 2026 | globenewswire.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 TrialsJune 23, 2026 | markets.businessinsider.comQuantum BioPharma (QNTM) Advances Novel Multiple Sclerosis Therapy Toward Phase 2 TrialsJune 23, 2026 | finance.yahoo.comQuantum BioPharma Ltd. (NASDAQ: QNTM) Developing Patented, First-in-Class MS Treatment That Offers Different ApproachJune 23, 2026 | globenewswire.comQuantum BioPharma (QNTM) Advances Proprietary Therapy for MS TreatmentJune 9, 2026 | finance.yahoo.comQuantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) Builds Diversified Pipeline Across Neurological and Wellness MarketsJune 5, 2026 | markets.businessinsider.comQuantum BioPharma (QNTM) Builds Diversified Pipeline Across Neurological and Wellness MarketsJune 5, 2026 | finance.yahoo.comQuantum BioPharma (QNTM) Highlights Lucid-MS and unbuzzd(TM) Growth Opportunities on BioMedWire PodcastJune 3, 2026 | finance.yahoo.comIBN Announces Latest Episode of The BioMedWire Podcast Featuring Anthony Durkacz, Executive Co-Chair of Quantum BioPharma Ltd.June 2, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMRA, PLUR, NXTC, and QNTM Company DescriptionsBiomerica NASDAQ:BMRA$1.58 0.00 (0.00%) Closing price 07/24/2026 03:56 PM EasternExtended Trading$1.56 -0.02 (-1.26%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biomerica, Inc., a biomedical technology company, develops, patents, manufactures, and markets diagnostic and therapeutic products for the detection and/or treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and other medical complications; or to measure bacteria, hormones, antibodies, antigens, or other substances which may exist in the human body, stools, or blood in extremely small concentrations. It primarily sells its products for gastrointestinal diseases, food intolerances, and various esoteric tests at the physicians' offices and over-the-counter drugstores, and hospital/clinical laboratories. The company is also developing InFoods IBS, that uses a simple blood sample to identify patient-specific foods which may alleviate irritable bowel syndrome symptoms; and H. Pylori diagnostic test that indicates if a patient is infected with the H. Pylori bacteria. In addition, it develops products to indicate if a person has been infected by COVID-19. Biomerica, Inc. was incorporated in 1971 and is headquartered in Irvine, California.NextCure NASDAQ:NXTC$4.24 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.14 -0.10 (-2.36%) As of 07/24/2026 07:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.Pluri NASDAQ:PLUR$1.78 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.78 +0.00 (+0.28%) As of 07/24/2026 07:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Pluri Inc., a biotechnology company, engages in the development of placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions. It operates in the field of regenerative medicine, food-tech, and biologics and focuses on establishing partnerships that leverage its 3D cell-based technology to additional industries that require mass cell production. The company's development pipeline includes PLX-PAD, is composed of maternal mesenchymal stromal cells originating from the placenta that is currently under phase III study for orthopedic, phase II study for COVID-19, and phase I/II clinical study for Steroid-Refractory cGVHD indications; and PLX-R18, is composed of fetal MSC like cells originating from the placenta that is currently under phase I study for HCT and pilot study for ARS indications. It is also involved in the development of modified PLX cells. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.Quantum Biopharma NASDAQ:QNTM$2.99 0.00 (0.00%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$2.92 -0.07 (-2.34%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Quantum Biopharma Ltd. is a biotechnology pharmaceutical research and development company, which focuses on the cultivation, process, and sale of medical cannabis. It operates through the Biotechnology and Strategic Investments segments. The Biotechnology segment is involved in the research and development of the company's three drug candidates consisting of FSD-PEA, Lucid-PSYCH, and Lucid-MS. The Strategic Investments segment is focused on generating returns and cashflow through the issuance of loans secured by residential or commercial property. The company was founded by Thomas Fairfull, Zeeshan Saeed and Anthony J. Durkacz on October 20, 1994 and is headquartered in Toronto, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy RTX and Lockheed Earnings: Can Strong Guidance Reset the Defense Trade? Broadcom May Be the Biggest Winner From Alphabet's Earnings CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
